Trials / Completed
CompletedNCT02212249
Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 85 (actual)
- Sponsor
- University Hospital, Grenoble · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Ve-cadherin is expressed in endothelial cells. Systemic slerosis is a rare auto-immune disease with a endothelial dysfunction. This study is to evaluated the level of soluble VE-cadherin and VE-cadherin antibody in patients with systemic slerosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | soluble Ve cadherin | dosage of soluble VE cadherine in each arms |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2014-08-08
- Last updated
- 2016-03-24
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02212249. Inclusion in this directory is not an endorsement.